Jaime M. Poniachik Teller

@Lismarblue Inyecciones de oro

Un paciente acudió al hospital quejándose de dolor intenso en la rodilla, hinchazón y limitación del movimiento. Tras la exploración física, el médico solicitó una radiografía de la zona afectada para determinar la causa. ¿Qué muestra la imagen? ¿Conoces cuál es el diagnóstico?

Les cuento que próxima semana sale en librerías mi primer libro, una crónica de la crisis de la salud en Chile para tod@s los que quieren entender los problemas (y virtudes) de nuestro sistema de salud, contado desde Pinochet a Boric. Escrito junto a la gran @mramosarellano

Review: Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.11…

HFpEF is a multiorgan syndrome. Obesity drives pathophysiology across 6 domains: metabolic dysfunction, mitochondrial impairment, vascular stiffness, cardiac remodeling, skeletal muscle abnormalities & chronic inflammation. onlinelibrary.wiley.com/doi/abs/10.100…

GLP-1 was just the beginning. We’re now engineering multi-pathway metabolic drugs that don’t just reduce weight—they reprogram systemic biology. Obesity → metabolism → ageing. Same network. New frontier. @AEEHLiver @sepdigestiva @EASLnews @AASLDtweets nature.com/articles/s4158…

The genetics of obesity: This new @NatMetabolism review shows obesity is highly heritable, with more than 85 monogenic forms and over 1,000 GWAS loci, and is rapidly opening the door to true precision medicine (MC4R agonists, PRSs, genotype-guided therapies) for our patients living with obesity. nature.com/articles/s4225…

Semaglutide in MASH: not just about weight loss. This study shows liver benefits persist without weight reduction—and disappear when intrahepatic GLP-1 signaling is blocked. We may have been measuring the wrong surrogate all along. @AEEHLiver sciencedirect.com/science/articl…

Clinical Use of Noninvasive Testing for Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease - Clinical Gastroenterology and Hepatology cghjournal.org/article/S1542-…

@Liver_Screen results finally out in @TheLancet 🔎screening for liver fibrosis ✅30,199 adults 🇪🇺9 countries ⚠️4.6% ⬆️ liver stiffness 🤕1.6% confirmed chronic liver disease with fibrosis ❌Obesity, diabetes and 🍻🍷🥃 main risk factors 👇🏻 thelancet.com/journals/lance…

בשביל מלחמה לא צריך שותפות יהודית-ערבית, אבל בשביל השלום חייבים שותפות יהודית-ערבית. התרגשתי לנאום הערב בכיכר הבימה בתל אביב, מול אלפי אזרחים אמיצים שמתנגדים למלחמה ומאמינים שיש אלטרנטיבה, שיש דרך אחרת. השלום הוא הדרך!

Love this paper 1. Checking ANA in everyone with elevated ALT is unhelpful, sometimes harmful, usually confusing 2. Biopsy when ALT <100 but ANA elevated is not useful 3. Autoimmune hepatitis is a clinical diagnosis and frequently made DESPITE biopsy findings

@karenmoure @tv_Amaro Totalmente de acuerdo : No hay que creerle a Hamas ni Hezbollah

Esto es Terrorismo. Da igual si es Israel o es ISIS. Es Terrorismo. Y en este caso es Israel. ¿Con qué derecho?!?

@tv_Amaro Es llamstivo tu falta de empatía con la población civil de Israel , si el gobierno del Líbano evitara el lanzamiento de misiles a Israel , no habría bombardeos ni invasión al Líbano …. Me sorprende tus opiniones viendo solo un lado de los conflictos

Mira: Israel ya ocupa el 14% del Líbano. ¿Con qué derecho? ¿Has visto como lo han bombardeado? ¿La cantidad de desplazados? Gaza, Cisjordania, lo mismo. ⬇️

New MASLD review by Rinella & Sookoian in @NatRevGastroHep outlines a personalized roadmap for #MASH care, integrating metabolic, liver-directed, and lifestyle therapies. With resmetirom & semaglutide available, there is opportunity for combo strategies, biomarkers & precision medicine. nature.com/articles/s4157…

The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. The limitations of biopsy have led to the development of noninvasive tests, which Drs. Laurent Castera, Mary E. Rinella, and Emmanuel A. Tsochatzis review. Learn more: nej.md/4hwZMgj

𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗔𝗴𝗼𝗻𝗶𝘀𝘁𝘀 𝗼𝗻 𝗚𝗹𝘆𝗰𝗮𝘁𝗲𝗱 𝗛𝗲𝗺𝗼𝗴𝗹𝗼𝗯𝗶𝗻 𝗟𝗲𝘃𝗲𝗹𝘀 Randomized, placebo-controlled trials of the glucagon-like peptide-1 (GLP-1) receptor agonists have provided strong evidence to support their use — in fact, they have presaged a mini-revolution in how type 2 diabetes is managed. 👉 nejm.org/doi/full/10.10… Tirzepatide was the first dual GLP-1 and glucose-dependent insulinotropic peptide receptor agonist approved for the treatment of type 2 diabetes on the basis of the SURPASS-1 (Tirzepatide [LY3298176] in Participants with Type 2 Diabetes Not Controlled with Diet and Exercise Alone) trial, a randomized, placebo-controlled trial of tirzepatide (administered in weekly doses of 5 mg, 10 mg, or 15 mg) paired with metformin for treatment of type 2 diabetes (seen in figure). Tirzepatide reduced glycated hemoglobin levels by as much as 2 percentage points and was superior to placebo at all dose levels. At 40 weeks, nearly 90% of participants had glycated hemoglobin levels of less than 7.0%, a change that was associated with profound weight loss. Read the Review Article “GLP-1 Receptor Agonists” by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, from @TuftsMedSchool and the Maine Medical Center Institute for Research: nejm.org/doi/full/10.10…

GLP1 agonists - April 2026 NEJM review 🆕 1️⃣ Physiology ⚙️ 2️⃣ GLP1 + GIP effects 💪 3️⃣ Side effects ⚠️ 📸: nejm.org/doi/full/10.10…

Treatment of Helicobacter pylori Infection jamanetwork.com/journals/jama/…

Obesity pharmacotherapy from the @TheAACE diabetes algorithm: GLP‑1/GIP and GLP‑1 RAs produce ~10–20% weight loss with A1c reduction, while older agents like phentermine, orlistat, and naltrexone/bupropion have less efficacy and safety trade‑offs. This table helps matching the right medication to the right patient by comparing efficacy, cardiometabolic benefit, adverse effects, contraindications, and cost. sciencedirect.com/science/articl…